An interventional study of Extracorporeal shock wave in Carpal Tunnel Syndrome, sponsored by Tri-Service General Hospital. Withdrawn at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-13.
Sponsored by Tri-Service General Hospital · Not applicable, Interventional, and Treatment
Extracorporeal shock wave is a novel treatment for peripheral nerve entrapment. This study was designed to compare the efficacy of focused and radial extracorporeal shock wave for carpal tunnel syndrome.
Both focused and radial extracorporeal shock wave had been proved to treat carpal tunnel syndrome by several studies. However, there was no study comparing these two methods. Considering different mechanisms and costs, this randomized comparative trial would be conducted to compare the efficacy of focused and radial extracorporeal shock wave for carpal tunnel syndrome.
589 studies on the registry are indexed under Carpal Tunnel Syndrome; 139 are open to participants now.
Browse Carpal Tunnel Syndrome studies →Tri-Service General Hospital is the lead sponsor of 109 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
fESWT (0.05-0.29 mJ/mm2, 2000 shocks, 5 Hz)
Device: Extracorporeal shock wave
rESWT (2000shocks, 4 Bar, 5Hz)
Device: Extracorporeal shock wave
Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
Change from baseline of Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) at 24th weeks after treatment
Boston carpal tunnel syndrome questionnaire (BCTQ) is a frequently used patient-based questionnaire for measurement of carpal tunnel syndrome which encompasses two components. eleven questions and eight items were evaluated to rate the symptom severity scale (SSS) and functional status scale (FSS), respectively. Each question or item ranges from 1 to 5 with a higher score indicating severer symptom or a higher degree of disability. Total score of SSS ranges from 11-55 and FSS from 8-40. The mean of total SSS and FSS divided with each item score were used for further analysis.
Time frame: Change of the mean of total SSS and FSS from baseline at 24th weeks after treatment
Visual analogue scale (VAS)
Digital pain severity or paresthesia/dysthesia within 1 week prior to evaluation was evaluated using visual analog scale (VAS). Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain.
Time frame: Pre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment
Nerve conduction velocity
Change from baseline in conduction velocity of median nerve on 2nd, 4th, 8th,12th and 24th weeks after treatment.
Time frame: Pre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment
Cross-sectional area (CSA) of the median nerve
Change from baseline in cross-sectional area of the median nerve on 2nd, 4th, 8th, 12th and 24th weeks after treatment.
Time frame: Pre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment
Nerve conduction amplitude
Change from baseline in conduction amplitude of median nerve on 2nd, 4th, 8th,12th and 24th weeks after treatment.
Time frame: Pre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment
This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tri-Service General Hospital